Sino Biopharmaceutical moved two internally developed assets closer to commercialization in China, with the Center for Drug Evaluation accepting NDAs for TQB-2102 and TQH-2722. The submissions cover, respectively, a HER2 dual-epitope bispecific antibody-drug conjugate and an IL-4Rα monoclonal antibody. For TQB-2102, the filing indicates progress toward evaluation of a more complex HER2-directed modality that combines bispecific targeting with ADC payload delivery. For TQH-2722, the IL-4R pathway continues to attract interest as regulators evaluate next-generation inflammation and immune-modulating strategies. The developments matter because NDA acceptance can compress timelines to clinical and regulatory milestones in China’s system relative to earlier-stage disclosures. It also signals that Sino is managing a parallel advancement strategy across oncology-targeted and immune pathway programs. The company’s filings extend its effort to generate a fuller commercialization pipeline in China, where competitive intensity in antibody-drug conjugates and immune pathway biologics remains high.